Rising adoption of continuous venovenous hemofiltration (CVVH) among
critical care providers, to drive CRRT industry growth during forecast
period
The global
Continuous Renal Replacement Therapy Market is estimated to reach USD 1.53 billion by 2022; growing at a CAGR of 7.0% during the forecast period.
Continuous Venovenous Hemofiltration (CVVH)
The widespread adoption of this modality for the treatment of AKI due
to the procedural benefits poses such as high filtrate flow in CVVH
that enhances the performance of solute removal, highly effective for
the removal of large molecules from patients with reduced renal function
or kidney failure, solutes can be removed in large quantities while
easily maintaining a net zero or even a positive fluid balance in the
patient. Furthermore, growing demand of continuous venovenous
hemofiltration is augmented by its effectiveness in removing big
molecules while maintaining a positive fluid balance in patients and a
large number of ongoing research studies and clinical trials to
establish the safety and efficacy profile for CRRT products.
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=246917088
Continuous venovenous hemodiafiltration to register the highest CAGR during the forecast period
Continuous Venovenous Hemodiafiltration (CVVHDF)
In this modality, blood is passed through a hemofilter and a
dialysate is injected on the other side of the semi-permeable membrane,
combining the filtration and dialysis processes. Positive demand growth
of CVVHDF is driven by the key advantages such as better clearance of
medium-sized solutes as compared to hemodialysis (due to the combination
of hemofiltration with the continuous HD procedure), proper acid-base
balance without additional intervention, and a significant reduction in
CRRT-related phosphate depletion.
Continuous Venovenous Hemodialysis (CVVHD)
This technique removes solutes by diffusion using dialysates;
replacement fluids are not required in this therapy. Effectiveness of
this modality in removing small and medium-sized molecules, increasing
incidences of acute renal failure and lactic acidosis are the key
factors propelling the demand for CVVHD market.
Slow Continuous Ultrafiltration (SCUF)
SCUF primarily removes water from the bloodstream through
ultrafiltration. This process removes excess water at a very slow
ultrafiltration rate. The modest market share of this segment is mainly
due to several factors such as increasing use in resolving fluid
overloads, pulmonary edemas, & congestive heart failure; very low
adoption owing to insufficiencies in waste clearance considering the
severity of patients; and the ultrafiltrate utilized in SCUF is low,
which helps in maintaining the stability of a patient’s vital signs and
does not have any major side effects.
Comments
Post a Comment